PeptidePros
All Peptides

TB-500

Also known as Thymosin Beta-4 fragment · LKKTETQ

Marketed thymosin beta-4 fragment (LKKTETQ actin-binding motif) studied for soft-tissue repair in preclinical models.

Tier Cmed–high riskintermediateWADA S2
Tier C
Evidence
6-10 week phase
Protocol
med–high
Risk
subcut.
Route

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

Sequence Ambiguity

Significant sequence ambiguity exists for this product in the market. Vendors must specify exact peptide sequence, and products should not be assumed interchangeable with related full-length peptides or fragments.

Evidence visual

TB-500 evidence and risk matrix

intermediate researcher fit

Evidence

Tier C

Risk

med high

Regulatory

not approved

WADA

S2

FDA

unknown

Route

subcutaneous

Mixed evidence profile. Useful for comparison, not a standalone protocol decision.

Overview

TB-500 is often marketed as a thymosin beta-4-derived fragment, specifically the LKKTETQ actin-binding motif (residues 17-23). Clinical evidence for TB-500 per se is limited compared to full-length thymosin beta-4. Sequence ambiguity between TB-500 and full Tβ4 is a material concern — vendors must specify exact sequence. WADA classifies thymosin-β4 derivatives under growth factor modulators.

Decision path

Where TB-500 fits in the research path.

Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.

1 related goal
  1. 01

    Read evidence

  2. 02

    Check risk

  3. 03

    Compare options

  4. 04

    Build plan

Peptide research path

Decide whether TB-500 belongs in your plan.

Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.

Research Details

Mechanism of Action

Actin-binding domain effects (cell migration and angiogenesis signatures) proposed; clinical evidence limited.

Administration Routes

subcutaneous

Study Dose Range

Human evidence for TB-500 specifically is limited; thymosin beta-4 clinical work is more substantial.

Expected Effects

Soft-tissue repair and recovery signals in preclinical models.

Dosing Timeline

Preclinical: varies by injury model. Consumer timelines are speculative.

Contraindications

No established contraindications (insufficient data).

Adverse Effects

Limited safety data; sequence ambiguity adds quality risk.

Interaction Notes

Unknown/insufficient. Caution when combining with full-length thymosin beta-4 due to sequence overlap.

Cost at a glance

Typical cycle cost

$287.97

Estimated monthly

$143.98

Protocol style

6-10 week phase

Phase-based

Estimate confidence

High confidence

Assumes roughly 16 mg32 mg per cycle, using 2 tracked affiliated listings.

Modeled as a multi-week recovery block with possible taper or maintenance later.

Age, sex, and monitoring

Life-stage fit

Usually framed as a recovery compound for active adults rather than a later-life maintenance tool.

25-3435-4445-5455-64

Best fit age ranges: 25-34, 35-44, 45-54

65+

Experimental status and limited human evidence make this a poor fit for older adults.

Known Interactions

Caution

Thymosin Beta-4

TB-500 is often described as a thymosin beta-4 fragment/region; must confirm exact sequence and avoid mixing fragment vs full-length assumptions.

Caution

BPC-157

Commonly marketed as a stack/blend in consumer market; clinical interaction evidence limited; treat as uncertain.

Frequently Compared

Compare top

BPC-157

Tier C

Thymosin Beta-4

Tier B-C

MGF E-domain

Tier C

GHK-Cu

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Personalized peptide routing

Find the right path for TB-500.

Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.

  • Goal-matched compound and protocol recommendations.
  • Budget and sourcing filters before you leave the site.
  • PDF unlocks shown after your personalized result.
Take the quiz